Establishing prognostic models for intrahepatic cholangiocarcinoma based on immune cells

Table 1 Correlation between baseline characteristics and overall survival in patients with intrahepatic cholangiocarcinoma

Patient characteristic	1-year survival	1-year death	P value	3-year survival	3-year death	P value
Age
> 53 years	63	8	0.237	31	40	0.335
< 53 years	58	13		25	45
Sex
Male	80	16	0.388	35	61	0.248
Female	40	5		21	24
HBV
Yes	54	12	0.304	27	39	0.786
No	66	9		29	46
Smoking
Yes	28	5	11	9	24	0.095
No	92	16		47	61
Drinking
Yes	31	5	0.844	10	26	0.09
No	89	16		46	59
Family history
Yes	11	3	0.4391	4	10	0.369
No	109	18		52	75
WBC
Abnormal	22	5	0.5541	10	17	0.752
Normal	98	16		46	68
ALT
Abnormal	38	10	0.155	20	28	0.734
Normal	82	11		36	57
AST
Abnormal	39	12	0.03	18	33	0.419
Normal	81	9		38	52
AFP
> 400 μg/L	12	2	11	7	7	0.407
< 400 μg/L	108	19		49	78
CEA
Abnormal	22	4	11	9	17	0.556
Normal	98	17		47	68
CA199
Abnormal	57	11	0.68	24	44	0.3
Normal	63	10		32	41
Child-Pugh
Group A	62	18	0.004	56	80	0.002
Group B	58	3		0	15
Tumor necrosis
Yes	49	17	0.001	29	63	0.077
No	71	4		27	32
Tumor metastasis
Yes	58	17	0.006	47	69	0.112
No	62	4		9	26

¹Fisher test.

ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; AFP: Alpha-fetoprotein; CEA: Carcinoembryonic antigen; CA199: Carbohydrate antigen 199; HBV: Hepatitis B virus.